Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randa Bittar

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Antiviral Therapy|February 10, 2012
Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patientsRanda Bittar, Philippe Giral, Elisabeth Aslangul, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 21, 2012
Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in womenElise F Villard, Petra El Khoury, Emilie Duchene, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 2, 2013
Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levelsElise F Villard, Petra EI Khoury, Eric Frisdal, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|November 23, 2019
Antiatherogenic properties of high-density lipoproteins from arterial plasma are attenuated as compared to their counterparts of venous originDominique Bonnefont-Rousselot, Leila Benouda, Randa Bittar, et al.
AIDS (London, England)|June 29, 2012
Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitorRanda Bittar, Philippe Giral, Elisabeth Aslangul, et al.
Comptes Rendus Biologies|December 25, 2016
Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitorsRanda Bittar, Élisabeth Aslangul, Philippe Giral, et al.
Annales De Biologie Clinique|December 1, 2022
Chylopericardium or contamination by injectable lipid emulsion?Bertrand Lefrère, Randa Bittar, Antoine Levasseur, et al.
Infectious Diseases Now|February 17, 2025
Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIVVincent Guiraud, Delphine Sauce, Randa Bittar, et al.
Journal of Clinical Lipidology|May 1, 2017
Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemiaAntonio Gallo, Philippe Giral, Alain Carrié, et al.
Journal of Clinical Lipidology|September 29, 2016
Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levelsBoris Hansel, Dominique Bonnefont-Rousselot, Alexina Orsoni, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Antiviral Therapy|February 10, 2012
Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patientsRanda Bittar, Philippe Giral, Elisabeth Aslangul, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 21, 2012
Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in womenElise F Villard, Petra El Khoury, Emilie Duchene, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 2, 2013
Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levelsElise F Villard, Petra EI Khoury, Eric Frisdal, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|November 23, 2019
Antiatherogenic properties of high-density lipoproteins from arterial plasma are attenuated as compared to their counterparts of venous originDominique Bonnefont-Rousselot, Leila Benouda, Randa Bittar, et al.
AIDS (London, England)|June 29, 2012
Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitorRanda Bittar, Philippe Giral, Elisabeth Aslangul, et al.
Comptes Rendus Biologies|December 25, 2016
Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitorsRanda Bittar, Élisabeth Aslangul, Philippe Giral, et al.
Annales De Biologie Clinique|December 1, 2022
Chylopericardium or contamination by injectable lipid emulsion?Bertrand Lefrère, Randa Bittar, Antoine Levasseur, et al.
Infectious Diseases Now|February 17, 2025
Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIVVincent Guiraud, Delphine Sauce, Randa Bittar, et al.
Journal of Clinical Lipidology|May 1, 2017
Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemiaAntonio Gallo, Philippe Giral, Alain Carrié, et al.
Journal of Clinical Lipidology|September 29, 2016
Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levelsBoris Hansel, Dominique Bonnefont-Rousselot, Alexina Orsoni, et al.
Pageof 4